CLAIMS FOR 19904-015 NATL

1. (Amended) A ~~P~~preparation of mammalian cells possibly transfected with at least one gene coding for an active substance, to be administered systemically in a subject, characterised in that it comprises no aggregate of said cells of a size liable to induce transient or permanent malfunctions in said patent.

2. (Amended) The ~~P~~preparation of mammalian cells according to claim 1, characterised in that it comprises no aggregates of said cells of a size greater than approximately 200 microns, preferentially greater than 50 microns and more preferentially greater than 30 microns.

3. (Amended) The ~~P~~preparation of mammalian cells according to ~~any of~~ claims 1 ~~to~~ ~~2~~, characterised in that said cells are immortalised.

4. (Amended) The ~~P~~preparation of mammalian cells according to ~~any of~~ claims 1 ~~to~~ ~~3~~, characterised in that the cells are non-tumorigenic.

5. (Amended) The ~~P~~preparation of mammalian cells according to ~~any of~~ claims 1 ~~to~~ 4, characterised in that said cells are ~~chosen in the~~ selected from a group comprising mammalian endothelial cells and epithelial cells.

6. (Amended) The ~~P~~preparation of mammalian cells according to ~~any of~~ claims 1 ~~to~~ ~~5~~, characterised in that said cells are ~~chosen in the~~ selected from a group comprising cerebral and retinal cells.

7. (Amended) The ~~P~~preparation of mammalian cells according to any of claims 1 to 6, characterised in that said cells have undergone a biological, chemical or physical treatment preventing aggregate formation or specifically eliminating the aggregate of said

cells of a size greater than approximately 200 microns, preferentially greater than 50 microns and more preferentially greater than 30 microns, and then suspended in a medium enabling their survival and not favouring their re-aggregation.

8. (Amended) The ~~P~~preparation of mammalian cells according to claim 7, characterised in that the biological treatment consists of genetically modifying said cells with a nucleic acid sequence expressing an agent preventing aggregate formation or inhibiting the expression of an agent favouring the formation of aggregates of said cells.

9. (Amended) The ~~P~~preparation of mammalian cells according to claim 7, characterised in that the physical treatment consists of a filtration or screening.

10. (Amended) A ~~P~~pharmaceutical formulation to be administered systemically in a subject, characterised in that it comprises a cell preparation according to any of claims 1 to 9, combined in said formulation with a pharmaceutically acceptable vehicle enabling the survival of said cells and not favouring their re-aggregation.

11. (Amended) The [F]formulation according to claim 10 to be administered by the intra-arterial, advantageously intra-carotid, route, in a patient, ~~according to claim 10,~~ characterised in that it comprises a cell preparation comprising no aggregate of said cells greater than 50 microns in size and preferentially greater than 30 microns.

12. (Amended) The [F]formulation according to claim 10 to be administered by the intravenous route, in a subject, ~~according to claim 10,~~ characterised in that it comprises a cell preparation comprising no aggregate of said cells greater than 200 microns in size and preferentially greater than 100 microns.

13. (Amended) The [F]formulation according to any of claims 10 to 12, characterised in that it comprises of the order of 1000 to 300,000 cells per microlitre of formulation.

14. (Amended) The [Pharmaceutical] formulation according to any one of claims 10 to 13 to be administered systemically, advantageously by the intra-arterial route, in a gene therapy method for a disease of the central nervous system in a subject, ~~according to any of claims 10 to 13,~~ characterised in that the cells are transfected with at least one gene coding for an active substance in the treatment or prevention of a disease of the nervous system.

15. (Amended) The [F]formulation according to claim 14, characterised in the active substance or gene in the treatment or prevention of a disease of the nervous system is chosen form the growth factors, anti-apoptotic factors, killer genes, antiproteases, immunommodulators, tumour suppressor genes, genes inhibiting the cell cycle.

16. (Amended) The [F]formulation according to ~~any of~~ claims 14 ~~to 15~~, characterised in that it is assayed so as to enable an administration of 1 million to 200 million immortalised mammalian cells transfected with at least one gene coding for an active substance per kilogram of weight of the subject to be treated.